Table 2. The measurements of spectral quality and tissue fractions in measured VOIs in participants with MCDs and HC.
| Parameters | HC (n=25) | MCDs_NACS (n=29) | MCDs_lesion (n=29) |
PHC vs. MCDs_NACS | PHC vs. MCDs_lesion | P MCDs_NACS vs. MCDs_lesion |
|---|---|---|---|---|---|---|
| FWHM | 0.042±0.005 | 0.045±0.012 | 0.050±0.014 | 0.896 | 0.074 | 0.038* |
| SNR | 26.20±5.72 | 27.62±8.70 | 24.03±8.88 | 0.477 | 0.286 | 0.001* |
| GMV/total volume | 0.40±0.11 | 0.27±0.15 | 0.22±0.13 | <0.001* | <0.001* | 0.050 |
| WMV/total volume | 0.51±0.18 | 0.67±0.17 | 0.70±0.16 | 0.002* | <0.001* | 0.705 |
| GMV/(GMV + WMV) | 0.46±0.16 | 0.29±0.17 | 0.24±0.15 | <0.001* | <0.001* | 0.112 |
| WMV/(GMV + WMV) | 0.54±0.16 | 0.71±0.17 | 0.76±0.15 | <0.001* | <0.001* | 0.112 |
Data are presented as the mean ± standard deviation. *, P<0.05. VOIs, volumes of interest; MCDs, malformations of cortical development; HC, healthy controls; NACS, normal-appearing contralateral side; FWHM, full width at half maximum; SNR, signal-to-noise ratio; GMV, gray matter volume; WMV, white matter volume.